Feed / Theme
Confirmed

Healthcare Biotech

20 names are moving together; 65% are participating in the current session.

Co-movement

Observed intraday paths are not available for this group yet.

Members

TICKERCompanySectorTodayObserved activity
BAMBrookfield Asset Management IncFinancial Services+2.0%Group member
ODFLOld Dominion Freight Line, Inc.Industrials-1.7%Group member
EDHLEverbright Digital Holding LimiCommunication Services-5.2%Group member
TROWT. Rowe Price Group, Inc.Financial Services+2.1%Group member
MMacy's IncConsumer Cyclical+1.9%Group member
NEUNewMarket CorpBasic Materials-3.1%Group member
TRINTrinity Capital Inc.Financial Services+0.5%Group member
TPGTPG Inc.Financial Services+1.5%Group member
BNBrookfield CorporationFinancial Services+0.7%Group member
BMOBank Of MontrealFinancial Services+1.2%Group member
SAHSonic Automotive, Inc.Consumer Cyclical+1.6%Group member
BXBlackstone Inc.Financial Services+2.1%Group member
ANABAnaptysBio, Inc.Healthcare-10.2%Group member
ANROAlto Neuroscience, Inc.Healthcare-0.4%Most structurally connected
BSBRBanco Santander Brasil SAFinancial Services+1.0%Group member
CWHCamping World Holdings, Inc.Consumer Cyclical+0.7%Group member
ROKURoku, Inc.Communication Services-0.4%Group member
VCTRVictory Capital Holdings, Inc.Financial Services+6.3%Group member
GHRSGH Research PLCHealthcare+4.4%Group member
CABACabaletta Bio, Inc.Healthcare-3.8%Group member

Why we believe this

Cohort

20 names

Participation

65% this session

Observed history

1 daily builds

Filing coverage

15/20 members

credit / rates affecting interest expense

The decrease was primarily due to a decrease in interest income of $2.2 million , an increase in interest expense of $1.1 million , and an increase of $0.7 million related to debt extinguishment costs ($0.4 million of which was non-cash) for our Amended Term Lo an.

ANRO 10-K

credit / rates

Other movements of $631 million were predominantly due to credit facility drawdowns by BEP.

BAM 10-Q

restructuring affecting expense

The above decreases in research and development expenses were offset by: • an increase of approximately $1.0 million due to acquisition fees paid in connection with the Chase asset acquisition during the three months ended June 30, 2025 compared to amounts paid during the three months ended June 30, 2024 in connection with development milestones achieved under licensing agreements covering ALTO-101 and ALTO-203; and • an increase of approximately $0.7 million in salary and personnel related costs during the three months ended June 30, 2025 due to increased headcount as well as $0.2 million of severance costs and $0.1 million of non-cash stock-based compensation.

ANRO 10-Q

Healthcare Biotech can stay leader-led if TROW and the next software names fail to join while ANRO keeps moving.

Connected, outside the group

No high-confidence filing-linked non-members are available for this group yet.

History

Historical cohort observations are not available yet.